

## Prescribers Guide: EMIS Web

FDB OptimiseRx is fully integrated into the prescribing workflow within EMIS Web. OptimiseRx uses the medication prescribed and relevant patient specific criteria based on coding within the patient record (such as demographics, medication history, clinical conditions and lab results) to determine whether an OptimiseRx message should present to the prescriber at the point of care.

OptimiseRx messages appear for relevant patients when:

- initiating medication(s) for the first time
- reauthorising repeat medication(s)
- re-prescribing past medication(s)
- using EMIS regime review

Messages usually present at the start of the prescribing workflow, upon drug selection, to provide advice on local formulary status, best practice guidance or cost-effective prescribing based on local and national recommendations.

**Simple cost swaps** offering cheaper alternatives may also present at the end of the prescribing workflow after completion of dose and quantity information.

Where possible, messages will offer alternative products which prescribers can select in place of the original. Other messages may advise the medication is not recommended for that patient or offer relevant prescribing information (e.g. monitoring advice)

### Best Practice / Cost Saving Messages with Multiple Alternative Products

Click to expand to reveal the full message      **Headline Message**      Click this box to reveal the Alternative Products

Best practice guidance

**FDB OptimiseRx**


Selected drug - **Omeprazole 20mg dispersible gastro-resistant tablets**

Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective.

Accept    Reject

Icon indicates Best Practice or Cost Saving messages      Reject button for individual messages

Selected drug - **Omeprazole 20mg dispersible gastro-resistant tablets**

 **Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective.** ✔ Accept ✘ Reject

---

**Source** View reference information

Dispersible and orodispersible tablets should be reserved for patients with swallowing difficulties. The product literature for Losec MUPS dispersible tablets states that both omeprazole formulations are bioequivalent. Based on treatment doses of the two agents as detailed in their product literature, for most conditions (excluding Zollinger-Ellison syndrome and other hypersecretory conditions), omeprazole 20mg may be considered equivalent to lansoprazole 30mg: dose adjustment may be necessary depending on the specific condition being treated and patient response.

[View the triggered rule for this patient](#)


Click to view the patient attributes which triggered the message

Click to access the source of the Best Practice Guidance

## To display and select from the Alternative Products list

Click "Accept" to reveal the Alternative Products

Selected drug - **Omeprazole 20mg dispersible gastro-resistant tablets**

 **Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective.** ✔ Accept ✘ Reject

---

**Source** View reference information

Dispersible and orodispersible tablets should be reserved for patients with swallowing difficulties. The product literature for Losec MUPS dispersible tablets states that both omeprazole formulations are bioequivalent. Based on treatment doses of the two agents as detailed in their product literature, for most conditions (excluding Zollinger-Ellison syndrome and other hypersecretory conditions), omeprazole 20mg may be considered equivalent to lansoprazole 30mg: dose adjustment may be necessary depending on the specific condition being treated and patient response.

[View the triggered rule for this patient](#)

Alternative drugs

Average cost saving: £142.98 Per Patient Per Year

Lansoprazole 30mg orodispersible tablets

Omeprazole 20mg gastro-resistant capsules

Proceed Cancel

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

Proceed Cancel

List of Alternatives Products

1. Click on the chosen Alternative Product
2. Click proceed

## Rejecting a Message

Upon rejecting a message, the prescriber is presented with the option to enter a rejection reason.

Providing feedback on the rejection of a message is an optional step. Any reasons entered will be made available in a report which the ICB/LHB Medicines Optimisation Team can use to assist in managing the configuration of OptimiseRx. FDB will also review these reasons and use to support message review and updates.

NB: Text entered here may also be recorded in the detailed drug history section of patient's medical record.

If prescribers don't want to enter feedback, they can simply click Reject then proceed without providing a reason.

Selected drug - **Omeprazole 20mg dispersible gastro-resistant tablets**

Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective. ✓ Accept ✗ Reject

**Source**  
 Dispersible and orodispersible tablets should be prescribed as detailed in their product literature, for most conditions (excluding Zollinger-Ellison syndrome). For most conditions (excluding Zollinger-Ellison syndrome), omeprazole 20mg dispersible tablets are equivalent to lansoprazole 30mg: dose adjustment is not required.

[View the triggered rule for this patient](#)

View reference information  
 Literature for Losec MUPS dispersible tablets as detailed in their product literature for Losec MUPS dispersible tablets as detailed in their product literature. Omeprazole 20mg may be considered as an alternative to lansoprazole 30mg in patients who cannot be treated and patient response.

Rejection reason  
 Enter freetext (optional)

Reject

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#) Proceed Cancel

## Simple Cost Saving Messages

Simple cost swap messages will appear after entering the quantity and dosage information, as this data is used to identify savings opportunities. If available, a cheaper alternative will be presented.

Cost saving recommendation

FDB OptimiseRx<sup>®</sup>

**⚠ A more cost-effective alternative drug could be used.**

Original drug	Recommended alternative
<b>Name</b> Omeprazole 20mg gastro-resistant tablets	<b>Name</b> Omeprazole 20mg gastro-resistant capsules
<b>Class</b> Generic	<b>Class</b> Generic
<b>Cost</b> £5.94	<b>Cost</b> £0.88

**Saving** £5.06

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

Proceed with alternative
Proceed with original
Do not proceed

Replaces the original drug with the Alternative Product in the prescribing screen. Where an appropriate dose string match is found in EMIS Web the dosage will be carried forward on to the Alternative Product.

Continues prescribing of the original selected drug

Returns to the drug selection prescribing screen.

## To Acknowledge an Information Message

The Best Practice guidance in an Information message can be acknowledged by clicking OK

Selected drug - **Metformin 500mg tablets**

**+** **i** **Monitor the patient's serum creatinine; no result recorded within 1 year.**

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)



OK

## Formulary Message

Click here to expand to see more detail on why this message has appeared for this medication.

Your local organisation may have provided a hyperlink to the local formulary or other Best Practice guidance.

Selected drug - **Adoport 0.5mg capsules (Sandoz Ltd)**

  **The selected product is classified as RED.**

**Source**

Only suitable for use within hospital or specialist care setting.

[View the triggered rule for this patient](#)

[View reference information](#)

Disclaimer: The Medicines Optimisation module is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance. [View full disclaimer.](#)

OK

Click OK to acknowledge local formulary message and follow relevant advice.